Bracco Boosts Precision Medicine Portfolio With $450M Deal For Blue Earth
Bracco Imaging is paying $450m to buy Blue Earth Diagnostics from London-listed venture capital firm Syncona Investment Management Ltd.
You may also be interested in...
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.